Unnamed stage
$16m
$16m cash injection to progress first-in-class therapy for inflammation and fibrosis
Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.